Description of the medicine: Buspirone (Buspirone)
8- [4- [4- (2-Pyrimidinyl) -1-piperazinyl] butyl] -8-azaspiro [4,5] decan-7,9-dione.
Synonyms: Buspar, Spitomin, Bespar, Buspar, Spitomin
It differs from benzodiazepine tranquilizers in selective anxiolytic (anti-anxiety) action, does not have anticonvulsant and muscle relaxant properties, and causes a less pronounced sedative effect.
The mechanism of action is not well understood.
When taken orally, it is rapidly and completely absorbed, although the bioavailability is only 4%, Cmax - 40-90 minutes, T1 / 2 - 2-3 hours; undergoes intensive biotransformation in the liver with the formation of an active metabolite (1-pyrimidinylpiperazine).
It is used mainly for the treatment of anxiety conditions.
Assign inside, starting with 0.005 g (5 mg) 2-3 times a day, gradually increasing the dose of 0.005 g (5 mg) every 2-3 days until the desired effect is achieved. The maximum daily dose of 0.06 g (60 mg).
The drug is usually well tolerated. Dyspepsia, chest pain, depression, muscle weakness, dizziness, fever, anxiety, and rarely “blurred” vision, insomnia, hallucinations, etc. are possible.
The drug is contraindicated in severe violations of the liver and kidneys.
Buspirone is not recommended for children and adolescents under the age of 18 years (due to lack of sufficient data).
Release form: tablets of 0.005 and 0.01 g (5 and 10 mg) (N. 10.60).